Role of NOS2 in pulmonary injury and repair in response to bleomycin

Nitric oxide (NO) is derived from multiple isoforms of the Nitric Oxide Synthases (NOSs) within the lung for a variety of functions; however, NOS2-derived nitrogen oxides seem to play an important role in inflammatory regulation. In this study, we investigate the role of NOS2 in pulmonary inflammati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Free radical biology & medicine 2016-02, Vol.91, p.293-301
Hauptverfasser: Guo, Changjiang, Atochina-Vasserman, Elena, Abramova, Helen, George, Blessy, Manoj, Veleeparambil, Scott, Pamela, Gow, Andrew
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 301
container_issue
container_start_page 293
container_title Free radical biology & medicine
container_volume 91
creator Guo, Changjiang
Atochina-Vasserman, Elena
Abramova, Helen
George, Blessy
Manoj, Veleeparambil
Scott, Pamela
Gow, Andrew
description Nitric oxide (NO) is derived from multiple isoforms of the Nitric Oxide Synthases (NOSs) within the lung for a variety of functions; however, NOS2-derived nitrogen oxides seem to play an important role in inflammatory regulation. In this study, we investigate the role of NOS2 in pulmonary inflammation/fibrosis in response to intratracheal bleomycin instillation (ITB) and to determine if these effects are related to macrophage phenotype. Systemic NOS2 inhibition was achieved by administration of 1400W, a specific and potent NOS2 inhibitor, via osmotic pump starting six days prior to ITB. 1400W administration attenuated lung inflammation, decreased chemotactic activity of the broncheoalveolar lavage (BAL), and reduced BAL cell count and nitrogen oxide production. S-nitrosylated SP-D (SNO-SP-D), which has a pro-inflammatory function, was formed in response to ITB; but this formation, as well as structural disruption of SP-D, was inhibited by 1400W. mRNA levels of IL-1β, CCL2 and Ptgs2 were decreased by 1400W treatment. In contrast, expression of genes associated with alternate macrophage activation and fibrosis Fizz1, TGF-β and Ym-1 was not changed by 1400W. Similar to the effects of 1400W, NOS2−/− mice displayed an attenuated inflammatory response to ITB (day 3 and day 8 post-instillation). The DNA-binding activity of NF-κB was attenuated in NOS2−/− mice; in addition, expression of alternate activation genes (Fizz1, Ym-1, Gal3, Arg1) was increased. This shift towards an increase in alternate activation was confirmed by western blot for Fizz-1 and Gal-3 that show persistent up-regulation 15 days after ITB. In contrast arginase, which is increased in expression at 8 days post ITB in NOS2−/−, resolves by day 15. These data suggest that NOS2, while critical to the development of the acute inflammatory response to injury, is also necessary to control the late phase response to ITB. •Loss of iNOS function attenuates the inflammatory cell recruitment early (day3–8) in the response to bleomycin.•Loss of iNOS functionleads to a failure to resolve the inflammatory response to bleomycin.•.iNOS is important in balancing classical and alternative inflammatory signaling.
doi_str_mv 10.1016/j.freeradbiomed.2015.10.417
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5059840</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0891584915010862</els_id><sourcerecordid>1767069006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-bc1295883ea8fb6b90faafb35facc557190c6675cdf0138138b3b0c30b0304743</originalsourceid><addsrcrecordid>eNqNUV1rFTEQDaLY2-pfkAVffNnrZLPJZhEEaWstlBaqPockO9FcdpM12S3035vLraV9EwaG4Zw583EIeU9hS4GKj7utS4hJD8bHCYdtA5QXZNvS7gXZUNmxuuW9eEk2IHtac9n2R-Q45x0AtJzJ1-SoEbwRnWg35Ow2jlhFV13ffG8qH6p5HacYdLovxW4tSYehSjhrn_ZwwjzHkLFaYmVGjNO99eENeeX0mPHtQz4hP7-e_zj9Vl_dXFyefrmqbdvTpTaWNj2XkqGWzgjTg9PaGcadtpbzjvZghei4HRxQJksYZsAyMMCg7Vp2Qj4fdOfVlMsthiXpUc3JT2VhFbVXz5Hgf6tf8U5x4L1soQh8eBBI8c-KeVGTzxbHUQeMa1a0Ex2IHkAU6qcD1aaYc0L3OIaC2vugduqZD2rvwx4sPpTud083fez99_hCOD8QsPzrzmNS2XoMFgef0C5qiP6_Bv0FFQih7A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1767069006</pqid></control><display><type>article</type><title>Role of NOS2 in pulmonary injury and repair in response to bleomycin</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Guo, Changjiang ; Atochina-Vasserman, Elena ; Abramova, Helen ; George, Blessy ; Manoj, Veleeparambil ; Scott, Pamela ; Gow, Andrew</creator><creatorcontrib>Guo, Changjiang ; Atochina-Vasserman, Elena ; Abramova, Helen ; George, Blessy ; Manoj, Veleeparambil ; Scott, Pamela ; Gow, Andrew</creatorcontrib><description>Nitric oxide (NO) is derived from multiple isoforms of the Nitric Oxide Synthases (NOSs) within the lung for a variety of functions; however, NOS2-derived nitrogen oxides seem to play an important role in inflammatory regulation. In this study, we investigate the role of NOS2 in pulmonary inflammation/fibrosis in response to intratracheal bleomycin instillation (ITB) and to determine if these effects are related to macrophage phenotype. Systemic NOS2 inhibition was achieved by administration of 1400W, a specific and potent NOS2 inhibitor, via osmotic pump starting six days prior to ITB. 1400W administration attenuated lung inflammation, decreased chemotactic activity of the broncheoalveolar lavage (BAL), and reduced BAL cell count and nitrogen oxide production. S-nitrosylated SP-D (SNO-SP-D), which has a pro-inflammatory function, was formed in response to ITB; but this formation, as well as structural disruption of SP-D, was inhibited by 1400W. mRNA levels of IL-1β, CCL2 and Ptgs2 were decreased by 1400W treatment. In contrast, expression of genes associated with alternate macrophage activation and fibrosis Fizz1, TGF-β and Ym-1 was not changed by 1400W. Similar to the effects of 1400W, NOS2−/− mice displayed an attenuated inflammatory response to ITB (day 3 and day 8 post-instillation). The DNA-binding activity of NF-κB was attenuated in NOS2−/− mice; in addition, expression of alternate activation genes (Fizz1, Ym-1, Gal3, Arg1) was increased. This shift towards an increase in alternate activation was confirmed by western blot for Fizz-1 and Gal-3 that show persistent up-regulation 15 days after ITB. In contrast arginase, which is increased in expression at 8 days post ITB in NOS2−/−, resolves by day 15. These data suggest that NOS2, while critical to the development of the acute inflammatory response to injury, is also necessary to control the late phase response to ITB. •Loss of iNOS function attenuates the inflammatory cell recruitment early (day3–8) in the response to bleomycin.•Loss of iNOS functionleads to a failure to resolve the inflammatory response to bleomycin.•.iNOS is important in balancing classical and alternative inflammatory signaling.</description><identifier>ISSN: 0891-5849</identifier><identifier>EISSN: 1873-4596</identifier><identifier>DOI: 10.1016/j.freeradbiomed.2015.10.417</identifier><identifier>PMID: 26526764</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Bleomycin ; Lipopolysaccharides - pharmacology ; Lung - enzymology ; Lung - immunology ; Lung - pathology ; Lung Injury - chemically induced ; Lung Injury - enzymology ; Lung Injury - immunology ; Macrophage Activation ; Mice, Inbred C57BL ; Nitric Oxide Synthase Type II - physiology ; NOS2 inhibitor ; Pulmonary inflammation ; Regeneration ; S-nitrosylation ; Surfactant protein-D ; Transcriptome</subject><ispartof>Free radical biology &amp; medicine, 2016-02, Vol.91, p.293-301</ispartof><rights>2016</rights><rights>Copyright © 2016. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-bc1295883ea8fb6b90faafb35facc557190c6675cdf0138138b3b0c30b0304743</citedby><cites>FETCH-LOGICAL-c491t-bc1295883ea8fb6b90faafb35facc557190c6675cdf0138138b3b0c30b0304743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0891584915010862$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26526764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Guo, Changjiang</creatorcontrib><creatorcontrib>Atochina-Vasserman, Elena</creatorcontrib><creatorcontrib>Abramova, Helen</creatorcontrib><creatorcontrib>George, Blessy</creatorcontrib><creatorcontrib>Manoj, Veleeparambil</creatorcontrib><creatorcontrib>Scott, Pamela</creatorcontrib><creatorcontrib>Gow, Andrew</creatorcontrib><title>Role of NOS2 in pulmonary injury and repair in response to bleomycin</title><title>Free radical biology &amp; medicine</title><addtitle>Free Radic Biol Med</addtitle><description>Nitric oxide (NO) is derived from multiple isoforms of the Nitric Oxide Synthases (NOSs) within the lung for a variety of functions; however, NOS2-derived nitrogen oxides seem to play an important role in inflammatory regulation. In this study, we investigate the role of NOS2 in pulmonary inflammation/fibrosis in response to intratracheal bleomycin instillation (ITB) and to determine if these effects are related to macrophage phenotype. Systemic NOS2 inhibition was achieved by administration of 1400W, a specific and potent NOS2 inhibitor, via osmotic pump starting six days prior to ITB. 1400W administration attenuated lung inflammation, decreased chemotactic activity of the broncheoalveolar lavage (BAL), and reduced BAL cell count and nitrogen oxide production. S-nitrosylated SP-D (SNO-SP-D), which has a pro-inflammatory function, was formed in response to ITB; but this formation, as well as structural disruption of SP-D, was inhibited by 1400W. mRNA levels of IL-1β, CCL2 and Ptgs2 were decreased by 1400W treatment. In contrast, expression of genes associated with alternate macrophage activation and fibrosis Fizz1, TGF-β and Ym-1 was not changed by 1400W. Similar to the effects of 1400W, NOS2−/− mice displayed an attenuated inflammatory response to ITB (day 3 and day 8 post-instillation). The DNA-binding activity of NF-κB was attenuated in NOS2−/− mice; in addition, expression of alternate activation genes (Fizz1, Ym-1, Gal3, Arg1) was increased. This shift towards an increase in alternate activation was confirmed by western blot for Fizz-1 and Gal-3 that show persistent up-regulation 15 days after ITB. In contrast arginase, which is increased in expression at 8 days post ITB in NOS2−/−, resolves by day 15. These data suggest that NOS2, while critical to the development of the acute inflammatory response to injury, is also necessary to control the late phase response to ITB. •Loss of iNOS function attenuates the inflammatory cell recruitment early (day3–8) in the response to bleomycin.•Loss of iNOS functionleads to a failure to resolve the inflammatory response to bleomycin.•.iNOS is important in balancing classical and alternative inflammatory signaling.</description><subject>Animals</subject><subject>Bleomycin</subject><subject>Lipopolysaccharides - pharmacology</subject><subject>Lung - enzymology</subject><subject>Lung - immunology</subject><subject>Lung - pathology</subject><subject>Lung Injury - chemically induced</subject><subject>Lung Injury - enzymology</subject><subject>Lung Injury - immunology</subject><subject>Macrophage Activation</subject><subject>Mice, Inbred C57BL</subject><subject>Nitric Oxide Synthase Type II - physiology</subject><subject>NOS2 inhibitor</subject><subject>Pulmonary inflammation</subject><subject>Regeneration</subject><subject>S-nitrosylation</subject><subject>Surfactant protein-D</subject><subject>Transcriptome</subject><issn>0891-5849</issn><issn>1873-4596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUV1rFTEQDaLY2-pfkAVffNnrZLPJZhEEaWstlBaqPockO9FcdpM12S3035vLraV9EwaG4Zw583EIeU9hS4GKj7utS4hJD8bHCYdtA5QXZNvS7gXZUNmxuuW9eEk2IHtac9n2R-Q45x0AtJzJ1-SoEbwRnWg35Ow2jlhFV13ffG8qH6p5HacYdLovxW4tSYehSjhrn_ZwwjzHkLFaYmVGjNO99eENeeX0mPHtQz4hP7-e_zj9Vl_dXFyefrmqbdvTpTaWNj2XkqGWzgjTg9PaGcadtpbzjvZghei4HRxQJksYZsAyMMCg7Vp2Qj4fdOfVlMsthiXpUc3JT2VhFbVXz5Hgf6tf8U5x4L1soQh8eBBI8c-KeVGTzxbHUQeMa1a0Ex2IHkAU6qcD1aaYc0L3OIaC2vugduqZD2rvwx4sPpTud083fez99_hCOD8QsPzrzmNS2XoMFgef0C5qiP6_Bv0FFQih7A</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Guo, Changjiang</creator><creator>Atochina-Vasserman, Elena</creator><creator>Abramova, Helen</creator><creator>George, Blessy</creator><creator>Manoj, Veleeparambil</creator><creator>Scott, Pamela</creator><creator>Gow, Andrew</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160201</creationdate><title>Role of NOS2 in pulmonary injury and repair in response to bleomycin</title><author>Guo, Changjiang ; Atochina-Vasserman, Elena ; Abramova, Helen ; George, Blessy ; Manoj, Veleeparambil ; Scott, Pamela ; Gow, Andrew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-bc1295883ea8fb6b90faafb35facc557190c6675cdf0138138b3b0c30b0304743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Bleomycin</topic><topic>Lipopolysaccharides - pharmacology</topic><topic>Lung - enzymology</topic><topic>Lung - immunology</topic><topic>Lung - pathology</topic><topic>Lung Injury - chemically induced</topic><topic>Lung Injury - enzymology</topic><topic>Lung Injury - immunology</topic><topic>Macrophage Activation</topic><topic>Mice, Inbred C57BL</topic><topic>Nitric Oxide Synthase Type II - physiology</topic><topic>NOS2 inhibitor</topic><topic>Pulmonary inflammation</topic><topic>Regeneration</topic><topic>S-nitrosylation</topic><topic>Surfactant protein-D</topic><topic>Transcriptome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guo, Changjiang</creatorcontrib><creatorcontrib>Atochina-Vasserman, Elena</creatorcontrib><creatorcontrib>Abramova, Helen</creatorcontrib><creatorcontrib>George, Blessy</creatorcontrib><creatorcontrib>Manoj, Veleeparambil</creatorcontrib><creatorcontrib>Scott, Pamela</creatorcontrib><creatorcontrib>Gow, Andrew</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Free radical biology &amp; medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guo, Changjiang</au><au>Atochina-Vasserman, Elena</au><au>Abramova, Helen</au><au>George, Blessy</au><au>Manoj, Veleeparambil</au><au>Scott, Pamela</au><au>Gow, Andrew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of NOS2 in pulmonary injury and repair in response to bleomycin</atitle><jtitle>Free radical biology &amp; medicine</jtitle><addtitle>Free Radic Biol Med</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>91</volume><spage>293</spage><epage>301</epage><pages>293-301</pages><issn>0891-5849</issn><eissn>1873-4596</eissn><abstract>Nitric oxide (NO) is derived from multiple isoforms of the Nitric Oxide Synthases (NOSs) within the lung for a variety of functions; however, NOS2-derived nitrogen oxides seem to play an important role in inflammatory regulation. In this study, we investigate the role of NOS2 in pulmonary inflammation/fibrosis in response to intratracheal bleomycin instillation (ITB) and to determine if these effects are related to macrophage phenotype. Systemic NOS2 inhibition was achieved by administration of 1400W, a specific and potent NOS2 inhibitor, via osmotic pump starting six days prior to ITB. 1400W administration attenuated lung inflammation, decreased chemotactic activity of the broncheoalveolar lavage (BAL), and reduced BAL cell count and nitrogen oxide production. S-nitrosylated SP-D (SNO-SP-D), which has a pro-inflammatory function, was formed in response to ITB; but this formation, as well as structural disruption of SP-D, was inhibited by 1400W. mRNA levels of IL-1β, CCL2 and Ptgs2 were decreased by 1400W treatment. In contrast, expression of genes associated with alternate macrophage activation and fibrosis Fizz1, TGF-β and Ym-1 was not changed by 1400W. Similar to the effects of 1400W, NOS2−/− mice displayed an attenuated inflammatory response to ITB (day 3 and day 8 post-instillation). The DNA-binding activity of NF-κB was attenuated in NOS2−/− mice; in addition, expression of alternate activation genes (Fizz1, Ym-1, Gal3, Arg1) was increased. This shift towards an increase in alternate activation was confirmed by western blot for Fizz-1 and Gal-3 that show persistent up-regulation 15 days after ITB. In contrast arginase, which is increased in expression at 8 days post ITB in NOS2−/−, resolves by day 15. These data suggest that NOS2, while critical to the development of the acute inflammatory response to injury, is also necessary to control the late phase response to ITB. •Loss of iNOS function attenuates the inflammatory cell recruitment early (day3–8) in the response to bleomycin.•Loss of iNOS functionleads to a failure to resolve the inflammatory response to bleomycin.•.iNOS is important in balancing classical and alternative inflammatory signaling.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26526764</pmid><doi>10.1016/j.freeradbiomed.2015.10.417</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0891-5849
ispartof Free radical biology & medicine, 2016-02, Vol.91, p.293-301
issn 0891-5849
1873-4596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5059840
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Bleomycin
Lipopolysaccharides - pharmacology
Lung - enzymology
Lung - immunology
Lung - pathology
Lung Injury - chemically induced
Lung Injury - enzymology
Lung Injury - immunology
Macrophage Activation
Mice, Inbred C57BL
Nitric Oxide Synthase Type II - physiology
NOS2 inhibitor
Pulmonary inflammation
Regeneration
S-nitrosylation
Surfactant protein-D
Transcriptome
title Role of NOS2 in pulmonary injury and repair in response to bleomycin
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T22%3A04%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20NOS2%20in%20pulmonary%20injury%20and%20repair%20in%20response%20to%20bleomycin&rft.jtitle=Free%20radical%20biology%20&%20medicine&rft.au=Guo,%20Changjiang&rft.date=2016-02-01&rft.volume=91&rft.spage=293&rft.epage=301&rft.pages=293-301&rft.issn=0891-5849&rft.eissn=1873-4596&rft_id=info:doi/10.1016/j.freeradbiomed.2015.10.417&rft_dat=%3Cproquest_pubme%3E1767069006%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1767069006&rft_id=info:pmid/26526764&rft_els_id=S0891584915010862&rfr_iscdi=true